Generex Biotechnology's Oral-lyn(TM) Matches Fast-Acting Insulin in Phase IIb Study

Clinical Trial of Patients with Type-1 Diabetes Shows Company's Mouth-Delivered Formulation Performing on Par with Multiple Daily Injections - Generex Biotechnology Corp(Nasdaq: GNBT), a leader in the area of buccal drug delivery, reported todayresults of a recently completed Phase IIb clinical study of Oral-lyn(TM) inwhich Oral-lyn(TM) s...

Continue to Generex Biotechnology's Oral-lyn(TM) Matches Fast-Acting Insulin in Phase IIb Study on Medical News Today.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz